Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019617 | 0.86 | TACR1 (0.49) | TACR1CYP3A4SIGMAR1 | |
| SCHEMBL4026665 | 0.83 | TACR1 (0.64) | TACR1CYP3A4SIGMAR1 | |
| SCHEMBL4021108 | 0.83 | TACR1 (0.64) | TACR1CYP3A4SIGMAR1 | |
| SCHEMBL4014218 | 0.83 | TACR1 (0.67) | TACR1CYP3A4SIGMAR1 | |
| SCHEMBL4014212 | 0.83 | TACR1 (0.67) | TACR1CYP3A4SIGMAR1 | |
| SCHEMBL4014194 | 0.83 | TACR1 (0.64) | TACR1CYP3A4SIGMAR1 | |
| SCHEMBL4016005 | 0.83 | TACR1 (0.67) | TACR1CYP3A4SIGMAR1 | |
| SCHEMBL4017295 | 0.83 | TACR1 (0.67) | TACR1CYP3A4SIGMAR1 | |
| SCHEMBL4016279 | 0.82 | TACR1 (0.56) | TACR1CYP3A4SIGMAR1 | |
| SCHEMBL4016274 | 0.82 | TACR1 (0.56) | TACR1CYP3A4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482365-B2 | 4-(2,2-Dimethyl-propylamino)-2-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide; specific antagonists of tachykinins receptor: substance P and neurokinins (NK1); antidepressant, anxiolytic agent; serotonin receptor inhibitor | GLAXO GROUP LIMITED (GB) | 2009-01-27 | — | — | US | claimed |
| US-7482365-B2 | 4-(2,2-Dimethyl-propylamino)-2-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide; specific antagonists of tachykinins receptor: substance P and neurokinins (NK1); antidepressant, anxiolytic agent; serotonin receptor inhibitor | GLAXO GROUP LIMITED (GB) | 2009-01-27 | — | — | US | disclosed |
| US-20050171153-A1 | Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases | GLAXO GROUP LIMITED (GB) | 2005-08-04 | — | — | US | disclosed |
| EP-1472222-A1 | PIPERIDYLCARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TACHYKINIM-MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066589-A1 | PIPERIDYLCARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TACHYKINIM-MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171153-A1 | Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases | NPSR1, NPY1R, NPY2R | TACR1 8/4885CYP3A4 2508/4885SIGMAR1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.